Elieser Hitoshi Watanabe

Elieser Hitoshi Watanabe

Auto-generated profile, based on publicly available information

Elieser Hitoshi Watanabe

Divisão de Nefrologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MMMaria Julia Morguetti
Maria Julia Morguetti
PNPrecil Neves
Precil Neves
IKIlana Korkes
Ilana Korkes
WPWallace Stwart Carvalho Padilha
Wallace Stwart Carvalho Padilha
LJLectícia Barbosa Jorge
Lectícia Barbosa Jorge
RMRegina S. Moisés
Regina S. Moisés
SUMMARY Lipodystrophies are characterized by complete or selective loss of adipose tissue and can be acquired or inherited. Familial partial lipodystrophy (FPLD) is a hereditary lipodystrophy commonly caused by mutations in the LMNA gene. Herein, we report two cases of FPLD associated with podocytopathies. Patient 1 was diagnosed with FPLD associated with the heterozygous p.Arg482Trp variant in LMNA and had normal glucose tolerance and hyperinsulinemia. During follow-up, she developed nephrotic-range proteinuria. Renal biopsy was consistent with minimal change disease. Patient [...] SUMMARY Lipodystrophies are characterized by complete or selective loss of adipose tissue and can be acquired or inherited. Familial partial lipodystrophy (FPLD) is a hereditary lipodystrophy commonly caused by mutations in the LMNA gene. Herein, we report two cases of FPLD associated with podocytopathies. Patient 1 was diagnosed with FPLD associated with the heterozygous p.Arg482Trp variant in LMNA and had normal glucose tolerance and hyperinsulinemia. During follow-up, she developed nephrotic-range proteinuria. Renal biopsy was consistent with minimal change disease. Patient

17 March 2020 in Research Square
Verified
Preprint
Open access
PDF file
EWElieser Hitoshi Watanabe
Elieser Hitoshi Watanabe
FCFernando Morbeck Almeida Coelho
Fernando Morbeck Almeida Coelho
HFHilton Leão Filho
Hilton Leão Filho
BBBruno Eduardo Pedroso Balbo
Bruno Eduardo Pedroso Balbo
PNPrecil Diego Neves
Precil Diego Neves
LOLuiz Fernando Onuchic
Luiz Fernando Onuchic
Background: Renal angiomyolipomas hemorrhage is strongly associated with their size and vascular constitution. Since previous studies showed that mTOR inhibitors can differentially act in distinct cell lines, we analyzed the effects of sirolimus on the volume of different components of angiomyolipomas in patients with tuberous sclerosis complex, including vascular structures. We retrospectively analyzed 23 angiomyolipomas from 10 patients treated with sirolimus. An approach based on a Hounsfield-unit threshold was used to classify angiomyolipomas in fat-rich, fat-poor and intermediate-fat tumors, and to categorize tumor compartments in fat rich, fat poor, intermediate fat and highly vascularized. Diameter variations were measured to assess the effects on aneurysmatic/ectatic vascular formations. Results: Volume reduction following treatment with sirolimus was higher in fat-poor than fat-rich angiomyolipomas. Tumor reduction was mainly determined by decrease of the fat-poor and highly-vascularized compartments, with a lesser contribution of the intermediate-fat component, while the volume of the fat-rich compartment increased. Broad liposubstitution was observed in some tumors. Massive reduction of aneurysmatic/ectatic vascular structures was observed, with disappearance of such lesions in most cases. Conclusions: Our study showed that sirolimus reduces the size of angiomyolipomas by decreasing primarily their highly-vascularized and fat-poor compartments. This effect is associated with a remarkable reduction of tumoral aneurysms/ectatic vessels and other vascular structures. Our findings revealed, therefore, the likely mechanism responsible for the reported risk-decreasing effect of mTOR inhibitors on angiomyolipoma bleeding. Our findings also expand the understanding the biology of this tumor, supporting a role for mTOR in maintenance, and maybe assembling, of blood vessels in angiomyolipomas.

9 July 2026 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
AMAline Grosskopf Monich
Aline Grosskopf Monich
EWElieser Hitoshi Watanabe
Elieser Hitoshi Watanabe
MCMariana Faucz Munhoz da Cunha
Mariana Faucz Munhoz da Cunha
LHLuciana Haddad
Luciana Haddad
ACAndrei Odevar Cêa
Andrei Odevar Cêa
FBFellype Barreto
Fellype Barreto
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder resulting from pathogenic variants in the TSC1 or TSC2 genes, leading to hyperactiva